Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis

Anil K. Sood, Guillermo N. Armaiz-Pena, Jyotsnabaran Halder, Alpa M. Nick, Rebecca L. Stone, Wei Hu, Amy R. Carroll, Whitney A. Spannuth, Michael T. Deavers, Julie K. Allen, Liz Y. Han, Aparna A. Kamat, Mian M K Shahzad, Bradley W. McIntyre, Claudia M. Diaz-Montero, Nicholas B. Jennings, Yvonne G. Lin, William M. Merritt, Koenraad De Geest, Pablo E. Vivas-Mejia & 4 others Gabriel Lopez-Berestein, Michael D. Schaller, Steven W. Cole, Susan K. Lutgendorf

Research output: Contribution to journalArticle

148 Citations (Scopus)

Abstract

Chronic stress is associated with hormonal changes that are known to affect multiple systems, including the immune and endocrine systems, but the effects of stress on cancer growth and progression are not fully understood. Here, we demonstrate that human ovarian cancer cells exposed to either norepinephrine or epinephrine exhibit lower levels of anoikis, the process by which cells enter apoptosis when separated from ECM and neighboring cells. In an orthotopic mouse model of human ovarian cancer, restraint stress and the associated increases in norepinephrine and epinephrine protected the tumor cells from anoikis and promoted their growth by activating focal adhesion kinase (FAK). These effects involved phosphorylation of FAKY397, which was itself associated with actin-dependent Src interaction with membrane-associated FAK. Importantly, in human ovarian cancer patients, behavioral states related to greater adrenergic activity were associated with higher levels of pFAKY397, which was in turn linked to substantially accelerated mortality. These data suggest that FAK modulation by stress hormones, especially norepinephrine and epinephrine, can contribute to tumor progression in patients with ovarian cancer and may point to potential new therapeutic targets for cancer management.

Original languageEnglish (US)
Pages (from-to)1515-1523
Number of pages9
JournalJournal of Clinical Investigation
Volume120
Issue number5
DOIs
StatePublished - May 3 2010
Externally publishedYes

Fingerprint

Anoikis
Focal Adhesion Protein-Tyrosine Kinases
Adrenergic Agents
Ovarian Neoplasms
Epinephrine
Norepinephrine
Neoplasms
Endocrine System
Growth
Actins
Immune System
Phosphorylation
Hormones
Apoptosis
Membranes
Mortality
human PTK2 protein

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Sood, A. K., Armaiz-Pena, G. N., Halder, J., Nick, A. M., Stone, R. L., Hu, W., ... Lutgendorf, S. K. (2010). Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. Journal of Clinical Investigation, 120(5), 1515-1523. https://doi.org/10.1172/JCI40802

Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. / Sood, Anil K.; Armaiz-Pena, Guillermo N.; Halder, Jyotsnabaran; Nick, Alpa M.; Stone, Rebecca L.; Hu, Wei; Carroll, Amy R.; Spannuth, Whitney A.; Deavers, Michael T.; Allen, Julie K.; Han, Liz Y.; Kamat, Aparna A.; Shahzad, Mian M K; McIntyre, Bradley W.; Diaz-Montero, Claudia M.; Jennings, Nicholas B.; Lin, Yvonne G.; Merritt, William M.; De Geest, Koenraad; Vivas-Mejia, Pablo E.; Lopez-Berestein, Gabriel; Schaller, Michael D.; Cole, Steven W.; Lutgendorf, Susan K.

In: Journal of Clinical Investigation, Vol. 120, No. 5, 03.05.2010, p. 1515-1523.

Research output: Contribution to journalArticle

Sood, AK, Armaiz-Pena, GN, Halder, J, Nick, AM, Stone, RL, Hu, W, Carroll, AR, Spannuth, WA, Deavers, MT, Allen, JK, Han, LY, Kamat, AA, Shahzad, MMK, McIntyre, BW, Diaz-Montero, CM, Jennings, NB, Lin, YG, Merritt, WM, De Geest, K, Vivas-Mejia, PE, Lopez-Berestein, G, Schaller, MD, Cole, SW & Lutgendorf, SK 2010, 'Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis', Journal of Clinical Investigation, vol. 120, no. 5, pp. 1515-1523. https://doi.org/10.1172/JCI40802
Sood, Anil K. ; Armaiz-Pena, Guillermo N. ; Halder, Jyotsnabaran ; Nick, Alpa M. ; Stone, Rebecca L. ; Hu, Wei ; Carroll, Amy R. ; Spannuth, Whitney A. ; Deavers, Michael T. ; Allen, Julie K. ; Han, Liz Y. ; Kamat, Aparna A. ; Shahzad, Mian M K ; McIntyre, Bradley W. ; Diaz-Montero, Claudia M. ; Jennings, Nicholas B. ; Lin, Yvonne G. ; Merritt, William M. ; De Geest, Koenraad ; Vivas-Mejia, Pablo E. ; Lopez-Berestein, Gabriel ; Schaller, Michael D. ; Cole, Steven W. ; Lutgendorf, Susan K. / Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. In: Journal of Clinical Investigation. 2010 ; Vol. 120, No. 5. pp. 1515-1523.
@article{7466bbe1143c43f597d665057e04cc98,
title = "Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis",
abstract = "Chronic stress is associated with hormonal changes that are known to affect multiple systems, including the immune and endocrine systems, but the effects of stress on cancer growth and progression are not fully understood. Here, we demonstrate that human ovarian cancer cells exposed to either norepinephrine or epinephrine exhibit lower levels of anoikis, the process by which cells enter apoptosis when separated from ECM and neighboring cells. In an orthotopic mouse model of human ovarian cancer, restraint stress and the associated increases in norepinephrine and epinephrine protected the tumor cells from anoikis and promoted their growth by activating focal adhesion kinase (FAK). These effects involved phosphorylation of FAKY397, which was itself associated with actin-dependent Src interaction with membrane-associated FAK. Importantly, in human ovarian cancer patients, behavioral states related to greater adrenergic activity were associated with higher levels of pFAKY397, which was in turn linked to substantially accelerated mortality. These data suggest that FAK modulation by stress hormones, especially norepinephrine and epinephrine, can contribute to tumor progression in patients with ovarian cancer and may point to potential new therapeutic targets for cancer management.",
author = "Sood, {Anil K.} and Armaiz-Pena, {Guillermo N.} and Jyotsnabaran Halder and Nick, {Alpa M.} and Stone, {Rebecca L.} and Wei Hu and Carroll, {Amy R.} and Spannuth, {Whitney A.} and Deavers, {Michael T.} and Allen, {Julie K.} and Han, {Liz Y.} and Kamat, {Aparna A.} and Shahzad, {Mian M K} and McIntyre, {Bradley W.} and Diaz-Montero, {Claudia M.} and Jennings, {Nicholas B.} and Lin, {Yvonne G.} and Merritt, {William M.} and {De Geest}, Koenraad and Vivas-Mejia, {Pablo E.} and Gabriel Lopez-Berestein and Schaller, {Michael D.} and Cole, {Steven W.} and Lutgendorf, {Susan K.}",
year = "2010",
month = "5",
day = "3",
doi = "10.1172/JCI40802",
language = "English (US)",
volume = "120",
pages = "1515--1523",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "5",

}

TY - JOUR

T1 - Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis

AU - Sood, Anil K.

AU - Armaiz-Pena, Guillermo N.

AU - Halder, Jyotsnabaran

AU - Nick, Alpa M.

AU - Stone, Rebecca L.

AU - Hu, Wei

AU - Carroll, Amy R.

AU - Spannuth, Whitney A.

AU - Deavers, Michael T.

AU - Allen, Julie K.

AU - Han, Liz Y.

AU - Kamat, Aparna A.

AU - Shahzad, Mian M K

AU - McIntyre, Bradley W.

AU - Diaz-Montero, Claudia M.

AU - Jennings, Nicholas B.

AU - Lin, Yvonne G.

AU - Merritt, William M.

AU - De Geest, Koenraad

AU - Vivas-Mejia, Pablo E.

AU - Lopez-Berestein, Gabriel

AU - Schaller, Michael D.

AU - Cole, Steven W.

AU - Lutgendorf, Susan K.

PY - 2010/5/3

Y1 - 2010/5/3

N2 - Chronic stress is associated with hormonal changes that are known to affect multiple systems, including the immune and endocrine systems, but the effects of stress on cancer growth and progression are not fully understood. Here, we demonstrate that human ovarian cancer cells exposed to either norepinephrine or epinephrine exhibit lower levels of anoikis, the process by which cells enter apoptosis when separated from ECM and neighboring cells. In an orthotopic mouse model of human ovarian cancer, restraint stress and the associated increases in norepinephrine and epinephrine protected the tumor cells from anoikis and promoted their growth by activating focal adhesion kinase (FAK). These effects involved phosphorylation of FAKY397, which was itself associated with actin-dependent Src interaction with membrane-associated FAK. Importantly, in human ovarian cancer patients, behavioral states related to greater adrenergic activity were associated with higher levels of pFAKY397, which was in turn linked to substantially accelerated mortality. These data suggest that FAK modulation by stress hormones, especially norepinephrine and epinephrine, can contribute to tumor progression in patients with ovarian cancer and may point to potential new therapeutic targets for cancer management.

AB - Chronic stress is associated with hormonal changes that are known to affect multiple systems, including the immune and endocrine systems, but the effects of stress on cancer growth and progression are not fully understood. Here, we demonstrate that human ovarian cancer cells exposed to either norepinephrine or epinephrine exhibit lower levels of anoikis, the process by which cells enter apoptosis when separated from ECM and neighboring cells. In an orthotopic mouse model of human ovarian cancer, restraint stress and the associated increases in norepinephrine and epinephrine protected the tumor cells from anoikis and promoted their growth by activating focal adhesion kinase (FAK). These effects involved phosphorylation of FAKY397, which was itself associated with actin-dependent Src interaction with membrane-associated FAK. Importantly, in human ovarian cancer patients, behavioral states related to greater adrenergic activity were associated with higher levels of pFAKY397, which was in turn linked to substantially accelerated mortality. These data suggest that FAK modulation by stress hormones, especially norepinephrine and epinephrine, can contribute to tumor progression in patients with ovarian cancer and may point to potential new therapeutic targets for cancer management.

UR - http://www.scopus.com/inward/record.url?scp=77951863320&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951863320&partnerID=8YFLogxK

U2 - 10.1172/JCI40802

DO - 10.1172/JCI40802

M3 - Article

VL - 120

SP - 1515

EP - 1523

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 5

ER -